Table 1.
Chromosomal translocations involving receptor tyrosine kinases
| Genetic abnormality | Chromosomal translocation | Disease type |
|---|---|---|
| TEL‐PDGFRβ | t(5;12)(q31;p12) | Atypical CML/CMML |
| HIP1‐PDGFRβ | t(5;7)(q33; q11.2) | |
| H4‐PDGFRβ | t(5;10)(q33; q11.2) | |
| Rabaptin‐5‐PDGFRβ | t(5;17)(q33;p13) | |
| CEV14‐PDGFRβ | t(5;14)(q33;q32) | AML relapse |
| FIP1L1‐PDGFRα | Interstitial deletion at 4q12 | CEL |
| KIF5B‐PDGFRα | t(4;10)(q12;p11) | |
| STRN‐PDGFRα | t(2;4)(p24;q12) | |
| ETV6‐PDGFRα | t(4;12)(q2?3; p1?2) | |
| BCR‐PDGFRα | t(4;22)(q12;q11) | CML‐like MPD |
| ZNF198‐FGFR1 | t(8;13)(p11;q12) | 8p11 myeloproliferative syndrome (EMS)/stem cell leukemia–lymphoma syndrome (SCLL) |
| FOP‐FGFR1 | t(6;8)(q27;p11) | |
| CEP110‐FGFR1 | t(8;9)(p11;q33) | |
| BCR‐FGFR1 | t(8;22)(p11;q22) | |
| FGFR3 overexpression | t(4;14)(p16.3; q32.3) | Multiple myeloma |
| TEL‐FGFR3 | t(4;12)(p16;p13) | PTCL?AML |
CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; AML, acute myeloid leukemia; CEL, chronic eosinophilic leukemia; MPD, myeloproliferative disorder; PTCL, peripheral T cell lymphoma.